EUS-guided ethanol ablation therapy for gastric stromal tumors

Hernandez-Ludena, Lucia; Consiglieri, Claudia F.; Gornals, Joan B.

doi:10.17235/reed.2017.5361/2017

Cited by 5 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In subepithelial gastrointestinal tumors (GIST), case reports of endosonographic fine needle injections (FNI) for ablation with ethanol[ 41 ] and RFA[ 42 ] have been successful in cases where patients either rejected or had prohibitive comorbidities to surgical resection. In this class of tumors, appropriately selected neoadjuvant and/or adjuvant tyrosine kinase inhibitors tend to have a favorable effect in disease control as well[ 15 ].…”

Section: Gastric Diseasementioning

confidence: 99%

Organ and function preservation in gastrointestinal cancer: Current and future perspectives on endoscopic ablation

Soliman,

Reddy

et al. 2024

World J Gastrointest Endosc

View full text Add to dashboard Cite

The escalating prevalence of gastrointestinal cancers underscores the urgency for transformative approaches. Current treatment costs amount to billions of dollars annually, combined with the risks and comorbidities associated with invasive surgery. This highlights the importance of less invasive alternatives with organ preservation being a central aspect of the treatment paradigm. The current standard of care typically involves neoadjuvant systemic therapy followed by surgical resection. There is a growing interest in organ preservation approaches by way of minimizing extensive surgical resections. Endoscopic ablation has proven to be useful in precursor lesions, as well as in palliative cases of unresectable disease. More recently, there has been an increase in reports on the utility of adjunct endoscopic ablative techniques for downstaging disease as well as contributing to non-surgical complete clinical response. This expansive field within endoscopic oncology holds great potential for advancing patient care. By addressing challenges, fostering collaboration, and embracing technological advancements, the gastrointestinal cancer treatment paradigm can shift towards a more sustainable and patient-centric future emphasizing organ and function preservation. This editorial examines the evolving landscape of endoscopic ablation strategies, emphasizing their potential to improve patient outcomes. We briefly review current applications of endoscopic ablation in the esophagus, stomach, duodenum, pancreas, bile ducts, and colon.

show abstract

Section: Gastric Diseasementioning

confidence: 99%

Organ and function preservation in gastrointestinal cancer: Current and future perspectives on endoscopic ablation

Soliman,

Reddy

et al. 2024

World J Gastrointest Endosc

View full text Add to dashboard Cite

show abstract

“… 119 Such direct comparison work has largely been abandoned and understudied, with widespread adoption of RFA and MWA for HCC. Other less common applications of PEI include ablating pancreatic tumors, 120 - 122 gastrointestinal stromal tumors, 123 and ablating the vascular supply to thyroid and parathyroid tumors. 124 , 125 Overall, PEI treatment has mild complications and adverse effects, which are caused by leakage of ethanol into surrounding tissues or organs.…”

Section: Ethanol Ablationmentioning

confidence: 99%

Locoregional Thermal and Chemical Tumor Ablation: Review of Clinical Applications and Potential Opportunities for Use in Low- and Middle-Income Countries

Quang,

Yang,

Mikhail

et al. 2023

JCO Global Oncology

View full text Add to dashboard Cite

show abstract

“…The amount of tissue required to make the GIST diagnosis is 1 cm 3 (about 5–10 core-needle biopsy specimens) [ 5 ]. EUS (endoscopic ultrasound)-guided fine-needle with 95% ethanol injection (FNI) therapy of GISTs in adults is an effective treatment method [ 87 , 88 ], however, its application in pediatric GISTs has not been set down yet.…”

Section: Updates To Surgical Approachmentioning

confidence: 99%

Latest Advances in the Management of Pediatric Gastrointestinal Stromal Tumors

Andrzejewska

Czarny

Derwich

2022

Cancers

View full text Add to dashboard Cite

Gastrointestinal stromal tumor is the most common mesenchymal neoplasm of the gastrointestinal tract, usually found in elderly adults. It is infrequent among pediatric patients and usually differs biologically from adult-type diseases presenting mutations of KIT and PDGFR genes. In this population, more frequent is the wild-type GIST possessing SDH, TRK, RAS, NF1 mutations, among others. Both tumor types require individualized treatment with kinase inhibitors that are still being tested in the pediatric population due to the different neoplasm biology. We review the latest updates to the management of pediatric gastrointestinal tumors with a particular focus on the advances in molecular biology of the disease that enables the definition of possible resistance. Emerging treatment with kinase inhibitors that could serve as targeted therapy is discussed, especially with multikinase inhibitors of higher generation, the effectiveness of which has already been confirmed in the adult population.

show abstract

EUS-guided ethanol ablation therapy for gastric stromal tumors

Cited by 5 publications

References 5 publications

Organ and function preservation in gastrointestinal cancer: Current and future perspectives on endoscopic ablation

Organ and function preservation in gastrointestinal cancer: Current and future perspectives on endoscopic ablation

Locoregional Thermal and Chemical Tumor Ablation: Review of Clinical Applications and Potential Opportunities for Use in Low- and Middle-Income Countries

Latest Advances in the Management of Pediatric Gastrointestinal Stromal Tumors

Contact Info

Product

Resources

About